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SECTION 1: INTRODUCTION 
This document addresses procedures for the audiological surveillance of hearing of infants and young children at 
risk for late onset or progressive permanent hearing loss (PHL). It is closely linked with the Ontario Infant Hearing 
Program (IHP) Protocol for Universal Newborn Hearing Screening, Auditory Brainstem Response Assessment (ABRA) 
Protocol, and the IHP protocol for Audiometric Assessment for Children Aged 6 to 60 Months with respect to risk 
indicators, hearing screening technology applied, screening bypass, and audiological assessment procedures.  
 
Infants are most often identified as having a risk indicator for late-onset or progressive PHL at the hearing 
screening stage. The designation of risk at the hearing screening stage informs which hearing screening technology 
(automated distortion product otoacoustic emission (ADPOAE) or automated auditory brainstem response (AABR)) 
is applied or whether hearing screening is bypassed and audiological assessment is initiated. If the infant passes 
the hearing screening or the audiological assessment is within normal limits and the risk factor screen is negative, 
and depending on the risk indicator, the infant may be discharged from the IHP or entered into a particular 
surveillance sequence (Basic or Intensive). Most Surveillance sessions will consist of visual reinforcement 
audiometry (VRA) and some early sessions will require an ABR assessment, both of which must be conducted by an 
IHP Audiologist authorized in those IHP protocols. If during a Surveillance session the child is identified as having 
PHL, the child will be offered the necessary intervention supports provided by the IHP as guided by current 
protocols and guidelines (i.e., Provision of Amplification Protocol, Language Development Services Guidelines). 
 
The scope of this document includes the details of the Surveillance procedures as funded by the Ministry of 
Children, Community and Social Services (MCCSS) for the IHP.   
 
1.1 VERSION HISTORY 
This version of the IHP High-Risk Surveillance Protocol (2019.01) supersedes all previous documents relating to 
high risk surveillance. It is substantially revised from previous documents related to Surveillance within the IHP. 
 
VERSION DATE  DOCUMENT TITLE PREVIOUS VERSION 
2014 High Risk Surveillance Redesign: 
Questions and Answers 
2012 Memo 
2012 Memo: Redesign of IHP High Risk 
Surveillance 
N/A 
2008 N/A Surveillance Implemented 
 
Revisions to this version are largely due to changes to IHP Universal Newborn Hearing Screening (UNHS) which 
now includes an additional risk factor screen using the dried blood spot (heel prick) sample collected by Newborn 
Screening Ontario (NSO). Additionally, changes to the risk indicator list which drives the choice of hearing 
screening technology, bypass of hearing screening, and Audiological Surveillance are included. 
 
1.2 REVISION SUMMARY FOR VERSION 2019.01 
Recent amendments to this Surveillance protocol are largely due to the introduction of the risk factor screen. 
 
TOPIC  DESCRIPTION SECTION 
RISK FACTOR 
SCREEN 
With parent/guardian consent, NSO will 
screen the dried blood spot from the 
infant’s heel prick for congenital 
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genetic mutations associated with 
permanent childhood hearing loss. 
RISK INDICATORS List of risk indicators has been updated. 3.2 
GROUP 1 RISK 
INDICATORS 
Infants with these risk indicators who pass 
their hearing screen will be discharged 
from the IHP. There will be further 
contact with the family if the infant 
screens positive on the risk factor screen. 
3.2.1 
GROUP 2 RISK 
INDICATORS 
A single-point Basic Surveillance is 
targeted at 15 to 18 months of age for 
infants who have these risk indicators. 
3.2.2 
GROUP 3 RISK 
INDICATORS 
Hearing screening is bypassed and 
surveillance will occur for infants with 
these risk indicators with the rate of 





Due to the updated risk indicators, 
surveillance sequences have been 
modified and are determined by the 




SECTION 2: SCOPE 
 
2.1 INFANT HEARING PROGRAM (IHP) CORE PRINCIPLES 
Audiological Surveillance, using electrophysiological or behavioural measures as required, shall be provided in 
accordance with the IHP core principles of informed parent/guardian choice and consent, timely provision of 
unbiased information based on the best available scientific evidence, and sensitivity to family culture and values. 
Further details about the IHP can be found in the IHP Guidance Document. 
 
2.2 WHAT IS AUDIOLOGICAL SURVEILLANCE? 
Audiological Surveillance is the proactive recall for an audiological assessment of young children who have been 
identified within the IHP as having a risk indicator associated with late-onset or progressive PHL. Surveillance is 
defined here to be Basic, which involves a single recall, or Intensive, involving a varying rate of recalls depending 
on the risk indicator. Both sequences involve a complete audiological assessment that is developmentally 
appropriate for the infant (e.g., auditory brainstem response assessment (ABRA), visual reinforcement audiometry 
(VRA), conditioned play audiometry (CPA), standard audiometry). 
In its broadest sense, Audiological Surveillance is a systematic process for the early detection of permanent 
hearing loss (PHL) that is not detected by UNHS. There are a variety of reasons why PHL may not be detected by 
UNHS. For instance, the child may not access UNHS through the IHP or the hearing loss was not present or 
detectable at the time of the hearing screen.  
 
Failure to detect hearing loss that is not yet present is not a false-negative screen. This situation is the major focus 
of surveillance, as are hearing losses that are too small at the time of hearing screen and hearing losses that are 
frequency-specific. Because surveillance is conducted using diagnostic hearing test technology and procedures 
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rather than screening technology and procedures, hearing losses that are present but undetectable by hearing 
screening tests are detectable in those children who are selected for surveillance. 
 
2.3 RISK FACTOR SCREEN 
In 2013, the IHP undertook a collaborative project with Newborn Screening Ontario (NSO) and determined that it 
was feasible for NSO to detect causes of PHL through blood spot screening including selected genetic mutations 
and congenital cytomegalovirus (cCMV). The dried blood spot is already used to detect many other treatable 
diseases and disorders in newborns. The addition of some genetic mutations known to cause PHL in infants as well 
as cCMV, which is the leading environmental cause of PHL, will help ensure that follow-up occurs for infants who 
pass UNHS and have a likelihood of late-onset or progressive PHL. 
The goal of implementing the risk factor screen in newborns is to improve the program’s risk assessment process. 
It will allow for earlier and more accurate identification of infants with specific risk indicators for PHL and their 
subsequent assessment or surveillance monitoring. 
Phase 1 was implemented in April 2018 and involved targeted cCMV screening for infants that had been referred 
for audiology assessment following a refer on the hearing screening and where parent/guardian explicit informed 
consent for the risk factor screen had been obtained. 
Phase 2 was implemented in July 2019 and involves offering the risk factor screen universally. With 
parent/guardian explicit informed consent, NSO will screen the dried blood spot for cCMV infection and several 
common mutations on three genes that are known to cause PHL in infants and young children. 
 
2.4 WHO CAN CONDUCT AUDIOLOGICAL SURVEILLANCE? 
Only Audiologists registered with the College of Audiologists and Speech Language Pathologists of Ontario 
(CASLPO) who are trained and authorized by the IHP to conduct this protocol AND at least one of the IHP 
Assessment protocols (ABRA, Audiometric Assessment for Children Aged 6 to 60 months) may provide Audiological 
Surveillance services with IHP funding. The assessment protocol for which an IHP Audiologist is authorized 
indicates which surveillance strategy (e.g., ABR or behavioural) the Audiologist is authorized to conduct as part of 
this protocol. The IHP Audiologist must personally conduct the testing and interpret the results. Students may also 
participate with full supervision from the IHP Audiologist. 
If an IHP Audiologist has been inactive in this or other IHP Assessment protocols for six months or more, the re-
training review procedures in the IHP Guidance Document will apply. 
Authorization for Surveillance may be withdrawn at the discretion of the MCCSS. 
 
2.5 PROTOCOL ADHERENCE IS A REQUIREMENT 
All IHP Surveillance must be conducted in adherence to this protocol as well as the IHP Assessment protocols; such 
adherence is an expectation for continued authorization to provide IHP services. Sufficient documentation of 
protocol adherence must be kept on file by the IHP Lead Agency/Audiologist to support clinical decision support 
and/or standard practice reviews conducted by DTCs when necessary. 
 
2.6 LEGITIMATE DEPARTURE FROM PROTOCOL 
It is acknowledged that case-specific situations that justify departure from mandatory protocol elements can arise. 
Such departures must be noted in the infant’s records with a brief explanation. All such notes must be accessible 
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2.7 PROCEDURAL CONCERNS 
Prior approval by MCCSS is required in order to substantively change any element of this protocol. Program-wide 
changes can occur only through MCCSS directive or by a systematic process that may include survey of 
Audiologists’ experiences or concerns, evidence review, and recommendation by a Designated Training Centre 
(DTC).  
IHP Protocols are evidence-based to the extent possible. Evidence is reviewed by the DTCs on an ongoing basis. 
This may result in specification of procedures that differ from opinions in published journals. Substantive issues 
will be addressed by new evidence review, re-examination of existing evidence, and/or provincial consensus 
development. Changes to IHP protocols are outside the mandate of regional IHP Lead Agency management and 
shall be authorized ONLY by modification of the relevant IHP protocol document (such as this document), which 
shall govern IHP Surveillance services throughout Ontario.   
 
2.8 NON-IHP SERVICES 
Hearing assessment services conducted by any person who is not an Audiologist authorized by the IHP shall not be 
funded by the IHP and shall not be deemed to provide a sufficient basis for subsequent management within the 
IHP. For this reason, and because of the prevalence of progressive hearing losses and/or conductive overlays in the 
pediatric population, IHP Audiologists shall re-test a child prior to making inferences about hearing status and/or 
candidacy for ongoing management. 
 
2.9 POPULATIONS TARGETED 
Candidates for surveillance include all Ontario-resident infants who have been identified, through the IHP UNHS 
protocol, Risk Factor Screen, or referral into the IHP, as having at least one of the IHP risk indicators (see Appendix 
B). Candidates must have: 
1) Passed UNHS; 
2) Bypassed UNHS and been found not to have PHL on audiology assessment ; or 
3) Referred on UNHS and been found not to have PHL on audiology assessment. 
 
Infants moving into Ontario or older siblings of infants with PHL identifed through the IHP must be assessed in the 
community (i.e., not through the IHP). Referral into the IHP is warranted if the child is eligible (e.g., has PHL and is 
younger than 6 years of age). Surveillance does not replace missed UNHS or retrospective audiology assessments 
for siblings of newly-identified infants with PHL through the IHP. 
 
2.10 TARGET DISORDERS 
The IHP target disorder set includes PHL of > 30 dB HL at 0.5, 1, 2, or 4 kHz in any ear, auditory neuropathy 
spectrum disorder (ANSD), and auditory brainstem pathway disorders that may be detectable using ABR 
techniques (see IHP ABRA Protocol). The target PHL includes conductive impairment associated with structural 
anomalies of the ear but does NOT include impairment attributable to minor, non-structural middle ear conditions. 
 
2.11 CONDUCTIVE HEARING LOSS 
The IHP is complementary to Ontario Health Insurance Plan (OHIP)-based, physician-driven audiology services and 
does not replace them. Purely conductive hearing loss is not an IHP target unless obviously or presumptively 
structural, such as in congenital atresia or if a syndrome associated with structural, conductive anomalies is 
identified or suspected. For minor conductive losses, discharge from the IHP with caregiver counseling and 
discretional referral to a physician is the norm. For more information, see the IHP Assessment protocols. 
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2.12 OBJECTIVE OF AUDIOLOGICAL SURVEILLANCE 
The main objectives of audiological surveillance are to: 
1) Determine whether further audiological assessment is required; and 
2) Potentially detect the presence of late onset or progressive PHL.  
The overall surveillance goes beyond audiometry itself and includes family counseling and information about 
follow-up. 
It is widely acknowledged that, overall, audiological surveillance is a resource-intensive method of identifying 
infants and young children at risk for PHL. The main reasons for this are that the majority of PHL associated with 
current risk indicators identifiable perinatally is congenital, the positive predictive values (PPV) of most current risk 
indicators for non-congenital PHL are very low, and the numbers of infants found to be at risk on some risk 
indicators are very large. Furthermore, the PHL case yield from any given single-point surveillance depends upon 
the distribution over age of the expression of the PHL (Boerst & Thorne, 2015). 
Multi-point surveillance has also been applied and is resource intensive. The Joint Committee on Infant Hearing 
(JCIH, 2000) revised their earlier surveillance recommendations to align with the impracticability of multiple 
surveillance events. As such, multi-point surveillance will be applied when infants are identified as having a risk 
indicator known to have a relatively high PPV and short PHL expression time-frames. 
A measure of this resource expenditure per case identified is the number needed to test (NNT) to find one PHL 
case in the group at risk on a given indicator and who did not refer on screening (Wood et al, 2013). For example, 
how many babies who passed newborn hearing screening and had a wide Family History risk indicator were seen 
for surveillance to identify one infant with PHL. In the 2.2 million babies analyzed retrospectively in the UK, the 
NNT for this risk indicator was 909 (Wood et al, 2013). The range median was about 500 for the other risk 
indicators. The corresponding median for babies who referred on screening was 4.9. This means that, overall, 
surveillance is at best about 1% as effective at identifying PHL as assessment is in babies who refer on screening in 
the UK sample. 
Another issue to consider is the harm accrued from proactively visiting unproductive care upon families who did 
not seek it. Such harms include anxiety and direct costs to large numbers of families for appointment attendance 
that yield no benefit to them. It is about the balance of relatively small harms to the many against the relatively 
large benefit for the few cases identified early and for whom intervention was effective. In surveillance, an option 
is to limit it to those risk indicators with the lowest NNTs. 
This protocol outlines the list of risk indicators used within the IHP and the surveillance sequence, if any, that must 
be applied. Depending on the risk indicator, the infant may not be involved in surveillance or may participate in a 
Basic or Intensive Surveillance sequence.  
 
2.13 TARGET AGE RANGE 
In practice, the overall target age range of children for potential surveillance within the IHP is from about three 
months corrected age to about five years of age. It should be noted that corrected age is to be calculated using 37 
weeks as full term (World Health Organization, 2018). Corrected age shall be calculated until the child turns two 
years chronological age. Risk indicators associated with PHL expression only beyond five years are not included in 
the IHP risk indicator list and the identification of PHL expressed beyond that limit is not within the purview of the 
IHP. Specific age ranges for successful completion of ABR and behavioural assessment can be found in the 
respective IHP Assessment protocols. 
It is noteworthy when considering the target age for surveillance that the lower the age, the smaller the 
proportion of infants with PHL already expressed. The others will likely be assessed as having normal hearing. 
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2.14 IHP DESIGNATED TRAINING CENTRES (DTC) 
DTCs are authorized by the MCCSS to provide IHP support, including advanced training, consultative and 
assessment referral services, IHP protocol support, and clinical decision support to IHP Audiologists and Regional 
Trainers for various components of the IHP. DTCs also conduct standard IHP practice reviews and implement audits 
of services as directed by MCCSS. 
The DTCs for ABRA and conditioned behavioural audiometry (CBA) are CHEO (Ottawa) and Humber River Hospital 
(HRH, Toronto). The National Centre for Audiology (NCA; Western University, London) is the DTC for Amplification, 
Hearing Screening, and Surveillance. 
2.15 IHP PROTOCOLS AND CASLPO GUIDELINES 
Since surveillance includes ABR or behavioural assessment to be conducted by an Audiologist, the procedures shall 
be practiced in full compliance with the requirements of both CASLPO and this protocol. IHP protocols may be 
more specific than CASLPO guidelines. Effort is made to ensure that IHP protocols do not conflict with CASLPO 
guidelines. Such conflicts may arise inadvertently and if any IHP Audiologist perceives such a conflict, the 
Audiologist shall notify the DTC promptly and the IHP will act to resolve the issue. 
 
2.16 INFECTION CONTROL STANDARDS 
Infection control practices are typically governed by site-specific, institutional or agency protocols and are outside 
the purview of this document. Generally accepted standards must be applied (CASLPO, 2010). 
 
2.17 APPROVED TEST ENVIRONMENTS 
Surveillance test areas must satisfy current ANSI standards for ABR or manual puretone audiometry (see IHP 
Assessment protocols for details). If deviations from this cannot be avoided, they must be clearly documented. If a 
refer on Surveillance is suspected in a test area that does not satisfy ANSI standards, it must be confirmed at a later 
date in a test area that meets the standards. 
 
2.18 CLINICAL RECORDS AND DATABASE REPORTING 
All audiometric records shall be maintained in a manner satisfying both CASLPO and the IHP. The records shall be 
maintained in hardcopy or, if electronic medical records are used, in secure data files. For Surveillance conducted 
using ABR, clinical records must include the test session listing of records that details the exact order of acquisition 
of tracings. For Surveillance conducted using behavioural audiometry, clinical records must include details of the 
procedure used to condition the child for VRA, the administration of control trials, the infant’s rate of correct 
responses on control trials, and a worksheet showing the administration of VRA including control trial 
administration. See IHP Assessment protocols for details. Records detailing interpretation of the Surveillance 
session and reporting of any necessary information to Healthy Child Development – Integrated Services for 
Children Information System (HCD-ISCIS) should also be available. 
 
2.19 PERSONAL HEALTH INFORMATION 
 
Management of all personal health information arising from the Surveillance process shall comply with local site 
and legislative requirements and those of CASLPO. Information communicated for approved monitoring and 
review procedures must be de-identified and code-referenced. All transmission of personally-identifiable 






Page | 10  
 
SECTION 3: PROTOCOL FOR AUDIOLOGICAL SURVEILLANCE 
 
3.1 RISK ASSESSMENT WITHIN THE IHP 
A risk indicator is an identifiable characteristic of the child or medical procedure used with the child that is 
associated with increased likelihood of PHL in that child greater than the likelihood in the newborn or child 
population as a whole. Risk indicators are identified by the Hearing Screener through document review, consulting 
nursing or medical staff, and talking to the family. 
With respect to initial hearing screening in the community, if the Hearing Screener’s first contact with the family is 
in a community facility, then the family/caregiver may be the only source of risk information other than the direct 
physical observation of the Hearing Screener, such as for an obvious malformation of the external ear. A confident 
and clear report of cleft palate by the family can be accepted. The remaining risk indicators require detailed 
medical knowledge and if the family cannot confirm a risk indicator exists, then the infant should not be 
considered At Risk. When in doubt, the decision should be No Risk and the default is ADPOAE screening. If a risk 
indicator is present, hearing screening is done using AABR.  
The purposes of risk assessment are to: 
1) Determine whether hearing screening should be bypassed; or 
2) Decide which hearing screening technology to use (i.e., ADPOAE or AABR); and 
3) Record information that will determine whether the infant should receive later audiological testing 
(surveillance) and, if so, what type of surveillance.  
The complete list of IHP risk indicators is provided below and in Appendix B for quick reference. Information about 
modifications from the previous list are described in the next sections. 
The items on the list are the only IHP risk indicators that exist; no other medical conditions, treatments, 
medications or family history items are acceptable. The only exception to this is a risk indicator specified by a 
physician, which is itself an IHP risk indicator.  
Note that an infant is not at risk unless and until at least one of the IHP risk indicators is determined to be present. 
If no such determination is yet available, the infant is not at risk. There is no such thing as ‘probable risk’, it is 
either present or it is considered not to be present. 
It is the Hearing Screener’s responsibility to collect risk information, but it can be assisted by a nurse, except for 
the Family History indicator, for which the Hearing Screener is responsible to ensure that the parent/guardian is 
questioned exactly as specified in the IHP Hearing Screening Protocol. The role of a nurse is to assist with the 
indicators related to specific medical conditions or procedures. 
 
For infants who did not undergo a risk assessment by the Hearing Screener either in the hospital or the 
community, it is the IHP Audiologist’s responsibility to conduct the risk assessment. It may be the case that the 
infant is directed to Audiology following a positive result on the dried blood spot from the risk factor screen. 
 
3.2 CURRENT IHP RISK INDICATORS 
The list of IHP risk indicators has been modified based on preliminary evidence review, expert consultation, and 
availability of IHP resources. In addition, the implementation of the risk factor screen has, in part, informed the 
screening, bypass, and surveillance procedures. The list of IHP risk indicators and surveillance steps are found in 
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Basic Surveillance if Pass 
Group 3: 
Bypass Screen, Refer to 
Audiology, Basic or Intensive 
Surveillance if Pass 
APGAR at 5 minutes ≤ 3 
Birthweight ≤ 1000g 
Congenital Diaphragmatic Hernia 
Family history of parent or sibling 
with PHL identified by 10 years of 
age 
Hypoxic Ischemic Encephalopathy 
(HIE) Sarnat II or III 
Intraventricular Hemorrhage (IVH) 
Grade III or IV 
Peri-ventricular Leukomalacia (PVL) 
Persistent Pulmonary Hypertension 
of the Newborn (PPHN) 
Ventilatory support with at least 
one of the following: 
 High frequency ventilation 
(HFJ, HFO, HFV) 
 Inhaled nitric oxide (iNO, 
NO) 




oxygenation (ECMO, ECLS) 
Hyperbilirubinemia meeting 
exchange criterion, whether 
exchanged or not 
Proven TORCHES infection 
(toxoplasmosis, rubella, herpes 
simplex virus, syphilis) except CMV 
Syndrome associated with PHL 
except CHARGE 
Atresia/microtia (screen of 
unaffected ear permitted) 
CHARGE Syndrome 
Proven Congenital 
Cytomegalovirus (cCMV) including 
cCMV screen positive on the dried 
blood spot 
Proven Meningitis 
Genetic Screen Positive 
 
3.2.1 GROUP 1 RISK INDICATORS 
Infants who are identified as having a Group 1 risk indicator will undergo an AABR screening procedure. If the 
hearing screening outcome is an overall ‘refer’ result, the infant is routed for an audiology assessment. If the 
hearing screening outcome is an overall ‘pass’ result and the risk factor screen is negative, the infant does not 
require audiological surveillance and is discharged from the IHP. The purpose of the Group 1 risk indicators is to 
determine the type of hearing screening technology the Hearing Screener applies. The infant will be re-directed for 
audiology assessment if the risk factor screen is positive following a ‘pass’ result on the hearing screening.  
3.2.2 GROUP 2 RISK INDICATORS 
Infants who are identified as having a Group 2 risk indicator will undergo an AABR screening procedure. If the 
screening outcome is an overall ‘refer’ result, the infant is routed for an audiology assessment. If the screening 
outcome is an overall ‘pass’ result, the infant enters into the Basic Audiological Surveillance sequence. 
 
The exceptions for Group 2 are CHARGE and CMV. CHARGE is considered a syndrome known to be associated with 
PHL. CMV is screened through the risk factor screen. Both are included as a separate risk indicator in Group 3 and 
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3.2.3 GROUP 3 RISK INDICATORS 
Infants who are identified as having a Group 3 risk indicator will bypass hearing screening and go directly to an IHP 
Audiologist for an ABR assessment. For certain risk indicators, like the ones in Group 3, the probability of PHL is 
very high, so the possibility of false-negative screening is increased. In that case, the infant must be flagged for 
routing directly to audiological assessment. Also, if the infant has atresia or microtia, it may be difficult or 
impossible to obtain a satisfactory eartip insertion. In view of the likelihood of insertion failure as well as the high 
PHL probability, the infant must be routed directly to Audiological Assessment. 
 
If the infant is determined to have PHL following the assessment, supports and services within the IHP will be 
offered including appropriate audiologic assessment follow-up which is not to be confused with surveillance. 
Children with PHL do not by definition require surveillance. If the audiology assessment reveals normal hearing in 
both ears, the infant enters into surveillance, which varies in frequency of appointments depending on the risk 
indicator. 
3.2.4 GENETIC MUTATION SCREEN POSITIVE FROM RISK FACTOR SCREEN 
Infants who screen positive for one of the included genetic mutations and who pass an initial audiology 
assessment will continue within the Intensive Surveillance sequence. This is because the likelihood of the infant 
developing PHL is high and they should be closely monitored. 
 
3.3 REVIEW OF UNCHANGED RISK INDICATORS 
APGAR at 5 minutes ≤ 3: This traditional, multi-component indicator largely reflects cardio-pulmonary function and 
has genuine, though limited, predictive relationships with long-term neurodevelopmental outcomes (Lieu, Ratnaraj 
& Ead, 2013). It is retained due to its accessibility and to lack of evidence that the other, more specific indicators 
here render it non-predictive. 
 
Birthweight ≤ 1000g: This accessible, non-specific indicator defines the Extremely Low Birthweight (ELBW) group 
(World Health Organization, 2004). 
 
Congenital Diaphragmatic Hernia (CDH): If the diaphragm does not close completely, body structures normally 
located below it can force their way up into the chest cavity, potentially compromising pulmonary and/or cardiac 
function. 
   
Hypoxic-Ischemic Encephalopathy (HIE): Moderate (Sarnat 2) or Severe (Sarnat 3): Encephalopathy is injury to brain 
structures, in this case due to lack of oxygen, caused by either insufficient blood supply (ischemia) or to insufficient 
oxygen-delivery capacity (hypoxemia), or both. Modified Sarnat is a severity scale. 
 
Intraventricular Hemorrhage (IVH): Grade III or IV: The ventricles generate and circulate cerebrospinal fluid. 
Especially in infants with low birth weight, the developing brain is vulnerable to deficient blood supply or oxygen 
levels. Consequent cell injury or death can cause bleeding into the ventricular lining, the ventricular fluid space 
itself or into nearby structures. Severity is graded I to IV, grades III and IV reflecting high risk of neurological and 
neurodevelopmental sequelae, as well as concurrent cochlear damage. 
  
Periventricular Leukomalacia (PVL): This is a brain injury characterized by coagulation or necrosis of nerve fibre 
tracts (axons, white matter) near the lateral ventricles. It can affect the fetus or newborn; premature newborns are 
at greater risk for this disorder. 
 
Persistent Pulmonary Hypertension of the Newborn (PPHN): This indicator relates to compromise of the normal 
post-partum circulatory transfer from the placenta to the lungs. It is a syndrome characterized by marked 
pulmonary hypertension and resultant hypoxemia. 
  
Ventilatory support with at least one of the following: 
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Inhaled Nitric Oxide (iNO): Nitric oxide (NO) is a colorless gas with a sweet odour. It is a powerful vasodilator with a 
strong relaxation effect on smooth musculature in the lungs, improving oxygenation. It may be used when 
ventilation has insufficient effectiveness. It can decrease the need for use of major, invasive techniques such as 
ECMO (see below). 
 
High-Frequency Jet Ventilation (HFV, HFJ, HFJV), High-Frequency Oscillatory Ventilation (HFV, HFO, HFOV): 
These are ventilation methods that deliver very small air volumes at very high repetition rates. It is used in a 
variety of situations including acute respiratory failure, respiratory distress syndrome, and risk of lung injury from 
conventional mechanical ventilation. It may serve as a ‘rescue’ when the conventional methods fail to achieve the 
desired result.  
 
Other risk indicator identified with confidence by a physician: Since the inception of the IHP, identification by a 
physician of risk that is not specified in the remainder of the IHP indicator list has been a distinct indicator in itself. 
It is impossible to list all conditions that incur valid risk of PHL. Even the indicators listed may be difficult or 
impossible to discover by any other means and for some potential indicators, the complexity and context-
specificity of disorder expression makes it impossible to derive a simple, practicable risk indicator. It is not 
intended that physicians adjust listed IHP indicators systematically, such as by declaring all unconfirmed meningitis 
cases as at risk for example. However, in situations such as pending but unavailable confirmatory test results, it is 
reasonable that if a physician judges the likelihood of risk confirmation in the individual case to be very high, then 
proactive declaration of risk is preferable to completely missing the risk. This is especially important given that 
HIV/measles/mumps have been deleted from the IHP risk indicator list (see below). 
  
Extracorporeal Membrane Oxygenation (ECMO) or Extracorporeal Life Support (ECLS): An invasive life-support 
technique in which blood is routed through an external gas exchange system for oxygenation and CO2 removal. In 
neonates, it is used in situations of severe respiratory failure for which less drastic methods have not succeeded. 
The duration of ECMO is typically 7-10 days, with the intent of life support during development or recovery of 
improved lung function. ECMO is frequently used in cases of PPHN and CDH. It is not well-understood whether 
ECMO itself or its indicating conditions (or both) are the main contributors to a high rate of PHL in ECMO survivors, 
including late-onset PHL.  
 
3.4 MODIFICATIONS TO CURRENT RISK INDICATORS 
Based on preliminary evidence review, program data, and availability of IHP resources, some risk indicators have 
been modified as follows: 
3.4.1 FAMILY HISTORY 
Family history of parent or sibling identified with PHL by 10 years of age: The main changes for this risk indicator is 
that infants receive an AABR screen and are discharged from the IHP rather than entering into Surveillance. This 
indicator is only useful if it is identified accurately, which can be a challenge if the appropriate information is not 
gathered by the Hearing Screener. As such, it has a long history of false-positive identification which imposes a 
significant strain on audiology assessment resources. A reduction in false-positive identification is expected with 
the inclusion of a genetic panel within the risk factor screen. The genetic panel within the risk factor screen focuses 
on selected common genetic mutations affecting three genes associated with significant and early PHL. These 
account for some of the most common recessive mutations but is not an exhaustive screen of either all mutations 
within the three genes, or all genes associated with pediatric PHL. In addition, the results of the risk factor screen 
may not be known at the time of the hearing screen. Therefore, it is imperative for the Hearing Screener to 
accurately identify a family history of hearing loss. 
  
In the absence of the result of the risk factor screen, the family history risk indicator should be identified by the 
Hearing Screener using a strictly-followed script for questioning of family members by IHP Hearing Screeners (see 
IHP Screening Protocol). Only clear and definite affirmative responses should be accepted as placing the infant at 
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An infant with a family history of PHL will be screened using AABR. If the infant passes the hearing screening, s/he 
will be discharged from the IHP and not included in a surveillance sequence. If the infant has a family history that is 
related to an inherited syndrome associated with late-onset or progressive hearing loss, the infant could still be 
eligible for surveillance when the syndrome is diagnosed by a physician. 
  
Those infants who screen positive on the risk factor screen for genetics will be re-directed to audiology for 
assessment regardless of any previous hearing screen outcome. Most of these children will be found to have 
hearing loss at birth. For those where the audiology assessment indicates that there is no hearing loss at that time, 
Intensive Surveillance will be scheduled. 
3.4.2 OTHERS 
Atresia/Microtia: The description for this risk indicator has changed from obvious craniofacial anomaly to 
atresia/microtia. While there are many abnormal features of the head and neck that may be associated with PHL 
risk, considerable expertise is required to identify them accurately. Also, the family may not be aware of the 
abnormality, unless it has already been clearly identified medically as syndromic. Therefore, given that medical 
records or medical/nursing staff may be consulted regarding syndromes, flagging of craniofacial malformations for 
this risk indicator is restricted to abnormalities that are obvious to the layperson, in particular, atresia and 
microtia. Atresia is identified with absent, closed, or slit-like external ear canal openings. Microtia includes absent 
or grossly malformed ear(s). Atresia and microtia can have varying grades of severity. 
 
CHARGE: The letters in CHARGE stand for: Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation 
of Growth and development, and Ear abnormalities and deafness. Infants with CHARGE have a very high incidence 
of PHL (~90%; e.g., Arndt et al, 2010; Blake et al, 1998; Holcomb et al, 2013). As well, these children usually have a 
very complex audiological profile, with the possibility of sensorineural, both temporary and/or permanent 
conductive, and ANSD components all present in the same child. As such, identification of this syndrome indicates 
a screening bypass and referral directly to audiology for assessment. 
 
Proven Congenital Cytomegalovirus (cCMV): Medical diagnosis of symptomatic cCMV infection external to the risk 
factor screen may occur in hospital. This remains a part of the risk assessment completed by the Hearing Screener 
and continues to be a bypass risk indicator. As described in the Risk Factor Screen section, cCMV can also be 
screened with parental consent. As a result, infants who screen positive for cCMV who are not identified in 
hospital will also have access to earlier identification and intervention, including possible treatment. Infants who 
screen positive for cCMV on the risk factor screen will bypass any further hearing screening and go directly for an 
audiology assessment. Many infants with cCMV will be asymptomatic (85-90%) with a 10% chance of developing 
PHL in childhood (Fowler et al, 2017). Ten to 15% of infants will have signs or symptoms of cCMV identified at birth 
such as rash, jaundice, or growth problems. Infants with symptomatic cCMV have a 30% chance of developing PHL 
(Fowler et al, 2017), which supports the need for different surveillance sequence timing for the two groups 
(Lanzieri et al, 2018). 
 
Proven Meningitis: Meningitis is inflammation of the membranes (meninges) lining the brain and spinal cord. It is 
an IHP risk indicator regardless of the specific pathogen involved (bacterial, viral, fungal, etc.), but only if the 
presence of the pathogen is proven by a medical record or medical report. Family verbal report is not sufficient. 
Neonatal meningitis is usually caused by vertical transmission during labor and delivery. It occurs most frequently 
in the days following birth and is more common in premature infants. If meningitis is suspected, antibiotics are 
typically initiated immediately and may eliminate the pathogen. If the pathogen’s presence has not been 
confirmed, the infant is not at IHP risk on this indicator. Between 25 and 50 % of survivors will manifest some type 
of morbidity in the first five years post-illness. Hearing loss is reported in about 25 % of cases (Bedford et al, 2001). 
Wellman et al (2003) recommended ABRA in all cases at four to six weeks post-recovery. 
 
Cleft palate: Cleft palate has a strong association with hearing loss, both permanent and temporary. Cleft lip alone 
(isolated cleft lip) should, however, be used as a cue for search of any medical record or medical/nursing report 
confirming presence of a cleft palate. Cleft lip was included in the previous list as a simple cue to possible cleft 
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palate, but isolated cleft lip with no palatal cleft is common and not associated with PHL. Therefore, cleft lip is 
hereby deleted as a risk indicator component. 
 
Hyperbilirubinemia meeting exchange criterion, whether exchanged or not: Bilirubin levels that are hazardous 
differ substantially according to the infant’s age and many other factors, including response to phototherapy. A 
fixed concentration criterion (e.g., ≥ 400 µmol/L) does not reflect optimally the overall risk of neurological 
sequelae. The modified wording reflects this clinical complexity. If an appropriate exchange criterion level is met, 
intensive phototherapy may be sufficiently effective to avoid the need for actual exchange transfusion. It is 
meeting an appropriate clinical criterion that constitutes the IHP risk indicator. Use of the term ‘kernicterus’ in a 
medical record is in itself too variable and subjective to be a useful indicator component. 
   
Other proven TORCHES infection: TORCH is the original acronym for the group of infections: Toxoplasmosis, 
Rubella, CMV, Herpes Simplex Virus (HSV), and Other. Variations on the acronym have been tried and evolving 
epidemiology has expanded the ‘Other’ group. For IHP risk indicator purposes, the only qualifying ‘Other’ infection 
for this factor is Syphilis (organism: T.Pallidum), therefore TORCHES is used. 
  
Syndrome associated with hearing loss in early childhood: About 50-60% of all hearing loss in childhood is genetic, 
about one fifth of which is syndromic (Toriello et al, 2004). There are hundreds of genetically-based syndromes 
associated with PHL in childhood. The vast majority are rare. Some of the more common, in approximate order of 
decreasing prevalence at birth are: Down, Pendred/Enlarged Vestibular Aqueduct (EVA), Stickler, CHARGE, Usher, 
Osteogenesis Imperfecta (OI), Goldenhar (OAVS), Waardenburg, Branchio-Oto-Renal (BOR)/Branchio-otic (BO), 
Alport, Treacher-Collins, Neurofibromatosis II (NF2), and Crouzon. CHARGE is now an indicator on its own (see 
above). 
 
3.5 DELETED RISK INDICATORS 
Based on preliminary evidence review, program data, and availability of IHP resources, the following risk indicators 
have been deleted from Ontario’s list. 
 
Gestation period ≤ 30 weeks: The 30 week criterion is too liberal. Gestational age estimates are inexact and 
gestational period per se is now considered to add negligible predictive value to that of the other indicators listed. 
 
Cleft lip: Cleft palate has a strong association with hearing loss, both permanent and impermanent, and remains on 
the list (see above). Cleft lip was included in the previous list as a simple cue to possible cleft palate, but isolated 
cleft lip with no palatal cleft is common and not associated with PHL. Cleft lip alone (isolated cleft lip) has been 
removed and should, however, be used as a cue for search of any medical record or medical/nursing report 
confirming presence of a cleft palate. 
 
Congenital HIV, Measles or Mumps infection: Although these infections are reoccurring in the general population 
due to the increase of non-vaccinated infants, the infections are often not proven at the time of the hearing 
screening. As such, if an infection is proven beyond the hearing screening period (birth to two months of age), the 
infant should be seen in the community for appropriate services. 
 
Severe neonatal asphyxia/hypoxia/respiratory failure/cardiopulmonary failure: This indicator was intended to 
increase the ease with which IHP Screeners could identify infants with hypoxia sufficient to cause serious risk of 
cochlear injury. However, the terms are now recognized as too subjective and less predictive than the other 
indicators included within the current list that relate to specific causes, sequelae or interventions associated with 
severe hypoxia. 
 
Severe neonatal sepsis: This indicator is now recognized to be neither sufficiently predictive of PHL nor specific. 
The association with PHL is only established if the septicemia leads to proven meningitis, which is a separate risk 
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Neonatal cancer treatment with cisplatin: The issue of PHL caused by either maternal cancer chemotherapy during 
pregnancy or, very rarely, cancer chemotherapy in the infant, is too complex and situation-specific to be addressed 
by a simple risk indicator. Additionally, infants undergoing this treatment are included in an ototoxic monitoring 
protocol which includes hearing. 
 
3.6 SURVEILLANCE SEQUENCES AND RISK INDICATORS 
Infants with no assigned IHP Risk Indicator for PHL will be screened using ADPOAE technology. About 95% of all 
infants are not at risk for PHL. Initial likelihood of PHL is small and the number of infants large. This favours use of 
an initial hearing screen using ADPOAE technology to quickly filter out all babies with the greatest probability of 
having normal hearing at that time. The AABR screen takes more time, skill and expense, but is more resilient to 
minor middle and outer ear dysfunction and will in turn eliminate many babies who are false-positive on ADPOAE.  
Infants who have a risk indicator from Group 1 will be screened using AABR technology. If the infant passes the 
hearing screen or is determined to have normal hearing at the audiology assessment, s/he will not enter into 
surveillance. S/he will be discharged from the IHP if they are also determined to have a negative result on the risk 
factor screen. Infants who are assigned an IHP risk indicator from Group 2 or 3 will enter into either Basic or 
Intensive Surveillance, which are described in detail in the following sections (see Table 2). Infants with a Group 3 
risk indicator will bypass screening and be routed directly for audiology assessment. If the infant is determined to 
have normal hearing at the initial assessment, s/he is entered into either a Basic or Intensive Surveillance sequence 
depending on the risk indicator. All surveillance appointments include a developmentally appropriate audiology 
assessment. A quick guide for the clinical application of the surveillance sequences for each IHP risk indicator can 




Page | 17  
 




Action Surveillance Classification Surveillance Sequence 
Group 1 
AABR Screen 





Surveillance if Pass 
 
Basic Sequence 






Bypass Hearing Screen 
Refer for Audiology Assessment 
 











Proven cCMV: Asymptomatic* 
Proven cCMV: Symptomatic* 
Genetic Screen Positive 
Proven Meningitis 





10 to 12 months, 15 to 18 




3 assessments at 3 month 
intervals, 15 to 18 months, 
3 years, 5 years 
 
Genetic Screen Positive: 
3 assessments at 3 month 
intervals, 15 to 18 months, 
3 years 
*Note: Audiologists should categorize infants with proven cCMV as asymptomatic unless otherwise notified. 
3.6.1 BASIC SURVEILLANCE 
Basic Surveillance is likely to be optimal if done between one and two years of age. This corresponds to the JCIH 
(2007) recommendations, among others (e.g., Sutton et al, 2012; Vos et al, 2015). It reflects the limited interest 
shown by families in attending assessments after too-lengthy periods of apparently normal hearing in their infants. 
Wood et al (2013) reported that only 55% of all families offered such appointments attended them. The resources 
expended in tracking and contacting all such families to no avail are not to be underestimated. It also takes 
account of the window of practicality for VRA in the target population. 
Infants identified as having a risk indicator from Group 2 and atresia/microtia and CHARGE syndrome from Group 3 
and who pass their hearing screen or audiological assessment will enter into Basic Surveillance. This single-point 
activity is targeted to occur between 15 to 18 months corrected age. Earlier than about 15 months limits the 
amount of PHL likely to be expressed. Later than about 18 months of age limits the likelihood of successful and 
efficient VRA, while play audiometry is still unlikely to be widely effective. 
The Basic Surveillance appointment will consist of a complete audiological assessment as described in the IHP 
Audiometric Assessment for Children Aged 6 to 60 months protocol. Briefly, in each ear, VRA shall be conducted via 
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air conduction at 500, 2000, and 4000 Hz. Case history, otoscopy, immittance, and DPOAEs shall also be obtained 
and the results interpreted accordingly to satisfy the cross-check principle (Norrix, 2015).  
Priority is given to obtaining VRA results with recommended cross-check from DPOAEs. If the result on Basic 
Surveillance is a pass in both ears, then the child shall be discharged from the IHP. No further surveillance 
appointments are required. If the child is identified as having PHL during the surveillance appointment, next step 
IHP supports and services shall be offered and no further surveillance is required. 
3.6.2 INTENSIVE SURVEILLANCE 
Infants identified as having a risk indicator from Group 3 (except atresia/microtia and CHARGE syndrome) and who 
pass their audiological assessment will enter into Intensive Surveillance. This surveillance sequence is multi-point 
and varies depending on the risk indicator. Regardless of the number of surveillance appointments, all infants with 
the relevant risk indicator from Group 3 will undergo a complete audiology assessment that is developmentally 
appropriate. That is, for infants under six months corrected age, an ABR assessment must be conducted and 
conditioned behavioural assessment must be conducted in infants six months and older, as developmentally 
appropriate. For either strategy, the current IHP Assessment Protocols apply (e.g., ABR Assessment and 
Audiometric Assessment for Children aged 6 to 60 months). 
The risk-dependent Intensive Surveillance sequences are as follows: 
1) Proven Meningitis: 3 assessments at 3 month intervals from the time of the first normal assessment 
2) Proven cCMV with no symptoms (asymptomatic)*: 10 to 12 months, 15 to 18 months, 3 years, and 5 years 
3) Proven cCMV with symptom(s) (symptomatic)*: 3 assessments at 3 month intervals from the time of the 
first normal assessment, then 15 to 18 months, again at 3 years and 5 years 
4) Genetic screen positive: 3 assessments at 3 month intervals from the time of the first normal assessment, 
then 15 to 18 months and again at 3 years 
 
* Audiologists should categorize infants with proven cCMV through the risk factor screen as asymptomatic unless 
otherwise notified. 
If normal hearing in both ears is confirmed during an Intensive Surveillance appointment within the sequence or a 
clinical decision is made that PHL is unlikely, the child shall be booked for the next surveillance appointment. If 
normal hearing in both ears is confirmed at the final appointment of the sequence, the child shall be discharged 
from the IHP. No further surveillance appointments are required. If the infant is identified as having PHL during any 
Intensive Surveillance appointment, next step IHP supports and services shall be offered and no further 
surveillance is required. For infants with proven meningitis who are identified as having PHL, the IHP Audiologist’s 
prompt referral to a cochlear implant program is recommended due to the possibility of ossification of the cochlea. 
Infants with incomplete or inconclusive results during the Intensive Surveillance appointment shall be rebooked for 
the next appointment within the sequence. 
 
3.7 NUMBER OF SURVEILLANCE ATTEMPTS 
Every effort should be made to complete the surveillance apointment in as few visits as possible. This should 
include parent counselling on how to prepare the child for the next visit and activities that can be done at home to 
help train the child to be better prepared to condition for the testing at the next visit (e.g., working on sound 
awareness). Review the relevant sections of the IHP Assessment protocols for helpful strategies for ABR and 
behavioural audiometry. 
Infants who have incomplete or inconclusive results during a surveillance appointment should be rebooked no 
more than two times for a total of three attempts. These appointments should be closely scheduled and occur 
within a three month time period if part of the Basic Surveillance sequence. For Intensive Surveillance, the child 
should be moved to the next scheduled surveillance visit. 
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If a complete assessment has not been achieved after the third attempt, the Audiologist must be prepared to make 
a clinical decision based on any information that was obtained. This may include ear-specific or soundfield 
responses, tympanometry, DPOAEs, acoustic reflexes, progress in listening skills, and parent reports on 
responsiveness to sound, which may include the LittlEARS auditory questionnaire (see IHP Provision of 
Amplification Protocol). If there is no information to indicate that PHL has developed, the child should either be 
moved to the next scheduled surveillance visit if the risk indicator requires Intensive Surveillance, or be discharged 
from the IHP with appropriate counselling to the family regarding monitoring the child’s responsiveness to sound, 
and clear documentation of the rational for the decision. If the family has future concerns about their child’s 
hearing, they should arrange for a hearing assessment in the community (i.e., not through IHP). 
If there is concern that a PHL may be present based on the information that was obtained, consideration of a 
natural sleep ABR or sedated ABR referral may be warranted. If the audiologist is unable to come to a clinical 
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APPENDIX B: IHP RISK INDICATORS FOR PERMANENT HEARING LOSS  
 





Group 1    
Apgar ≤ 3 at 5 minutes No No No 
Birthweight ≤ 1000 g No No No 
Congenital Diaphragmatic Hernia No No No 
Family history <10 yrs of age parent or sibling No No No 
Hypoxic Ischemic Encephalopathy (Sarnat II or III) No No No 
Intraventricular Hemorrhage (Grade III or IV) No No No 
Peri-ventricular Leukomalacia No No No 
Persistent Pulmonary Hypertension of the Newborn No No No 
Ventilatory support: iNO/NO, HFJ/HFO/HFV No No No 
Other risk identified by physician No No No 
Group 2    
Cleft Palate No Yes No 
Extracorporeal Membrane Oxygenation (ECMO) No Yes No 
Hyperbilirubinemia (exchange levels) No Yes No 
Other proven TORCHES infection No Yes No 
Syndrome associated with childhood PHL (not CHARGE) No Yes No 
Group 3    
Atresia/Microtia Yes Yes No 
CHARGE Syndrome Yes Yes No 
Proven Meningitis Yes No Yes 
Proven Congenital Cytomegalovirus: Asymptomatic  Yes No Yes 
Proven Congenital Cytomegalovirus: Symptomatic  Yes No Yes 
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APPENDIX C: QUICK GUIDE FOR CLINICAL APPLICATION OF SURVEILLANCE SEQUENCES  
 
Risk Indicator 
3 ax at 3 
month 
intervals 
10 – 12 
months 
15 – 18 
months 
3 years 5 years 
Group 1      
Apgar ≤ 3 at 5 minutes --- --- --- --- --- 
Birthweight ≤ 1000 g --- --- --- --- --- 
Congenital Diaphragmatic Hernia --- --- --- --- --- 
Family history <10 yrs of age 
parent or sibling 
--- --- --- --- --- 
Hypoxic Ischemic Encephalopathy 
(Sarnat II or III) 
--- --- --- --- --- 
Intraventricular Hemorrhage 
(Grade III or IV) 
--- --- --- --- --- 
Peri-ventricular Leukomalacia --- --- --- --- --- 
Persistent Pulmonary 
Hypertension of the Newborn 
--- --- --- --- --- 
Ventilatory support: iNO/NO, 
HFJ/HFO/HFV 
--- --- --- --- --- 
Other risk identified by physician --- --- --- --- --- 
Group 2      
Cleft Palate --- ---  --- --- 
ECMO --- ---  --- --- 
Hyperbilirubinemia (exchange 
levels) 
--- ---  --- --- 
Proven TORCHES infection --- ---  --- --- 
Syndrome associated with 
childhood PHL (not CHARGE) 
--- ---  --- --- 
Group 3      
Atresia/Microtia --- ---  --- --- 
CHARGE Syndrome --- ---  --- --- 
Proven Meningitis  --- --- --- --- 
Proven cCMV: Asymptomatic  ---     
Proven cCMV: Symptomatic   ---    















End of Surveillance Protocol MpB 2019  
